BCR-ABL1 TKIs in Relapsed/Refractory CML
EP. 1: CML as an Ideal Cancer for Targeted Therapy With TKI
June 24th 2019
EP. 2: BCR-ABL1-Targeted TKIs in Treatment of CML
June 24th 2019
EP. 3: Response Monitoring of Patients With CML Treated With TKIs
June 24th 2019
EP. 4: Importance of Compliance With TKIs in Treatment of CML
June 24th 2019
EP. 5: Resistance to Targeted-TKI Treatment in Patients With CML
June 24th 2019
EP. 6: Frontline Treatment for CML With BCR-ABL-Targeted TKIs
June 24th 2019
EP. 7: Role of Ponatinib in Treatment of R/R CML
June 24th 2019
EP. 8: Early Intervention With Ponatinib in Treatment of CML
June 24th 2019
EP. 9: Bosutinib Versus Ponatinib in R/R CML
June 24th 2019
EP. 10: Adverse Events of Second-Generation TKIs Used in Treating CML
June 24th 2019
EP. 11: Dose-Related Adverse Events With Ponatinib When Treating CML
June 24th 2019
EP. 12: Treatment-Free Remission & Toxicities of Discontinuing CML Therapy
June 24th 2019
EP. 13: Challenges in Management of Chronic Phase CML
June 24th 2019
